Crohn’s Disease: Full Disease Coverage

Crohn’s Disease: Full Disease Coverage

  • December 2017 •
  • 315 pages •
  • Report ID: 5336393 •
  • Format: PDF
Disease Overview
Crohn’s disease involves inflammation of the gastrointestinal (GI) tract, and most commonly affects the terminal ileum or colon.

Because Crohn’s disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active. Crohn’s disease is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.


Market Snapshot
Stelara is set to become the leading brand in Crohn’s disease as the longstanding anti-TNFs face biosimilar competition.
Infliximab – Remicade and its biosimilar versions – remains the most frequently prescribed biologic by surveyed physicians.
Crohn’s disease is an expanding global health problem, with prevalent cases forecasted to increase in the majority of analyzed countries.
Gastroenterologists intend to prescribe Stelara over Entyvio due to its faster onset of action and comparable safety.
Mongersen’s oral formulation and favorable safety will drive prescribing, despite its overall modest efficacy to date.